GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson’s Disease and Lewy Body Dementia

• DOI: 10.1371/journal.pone.0149349
• Publication Date: 2016-03-03T19:05:15Z
• Authors: Walter Maetzler; Willy Deleersnijder; Valérie Hanssens; Alice Bernard; Kathrin Brockmann; Justus Marquetand; Isabel Wurster; Tim W. Rattay; Lorenzo Roncoroni; Eva Schaeffer; Stefanie Lerche; Anja Apel; Christian Deuschle; Daniela Berg
• Keywords: GDF15; Lewy body; MMP9

Based on animal and ex-vivo experiments, Growth/Differentiation Factor-15 (GDF15, also called Macrophage Inhibitory Cytokine-1, MIC1), a member of the transforming growth factor-beta family, Matrix Metalloproteinase-9 (MMP9), matrix metalloprotease family may be potential markers for Lewy body disorders, i.e. Parkinson's disease with (PDD) without dementia (PDND) (DLB). GDF15 has prominent role in development, cell proliferation, differentiation, repair, whereas MMP9 degrades, as proteolytic enzyme, components extracellular matrix. In this study, cerebrospinal fluid levels 59 PDND, 17 PDD 23 DLB patients, well 95 controls were determined, associated demographic, clinical biochemical parameters. Our analysis confirmed already described association age gender. Corrected significantly higher than PDND intermediate patients. Within correlated positively at onset Parkinsonism dementia, Hoehn & Yahr stage t-Tau p-Tau levels, negatively Mini Mental State Examination. Remarkably, it does not relevantly correlate duration. was any these Cerebrospinal GDF15, but MMP9, marker disorders.